Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Monday, Analyst Ratings News reports. Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock performance was 2.84% in last session and finished the day at $46.74. Traded volume was 983,271 million shares in the last session and the average volume of the stock remained 300.25 million shares. Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider ownership is 0.40%.

Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) was a big mover last session, as the company saw its shares surge 22% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session. OHR Pharmaceutical Inc (NASDAQ:OHRP) rose 10.55 percent to $19.60 yesterday on volume of 391.41 million shares. The intra-day range of the stock was $17.48 to $19.71. OHR Pharmaceutical Inc (NASDAQ:OHRP) has a market capitalization of $391.41 million.

La Jolla Pharmaceutical Co (NASDAQ:LJPC) Monday said its randomized, placebo-controlled Phase 2 trial of GCS-100 in chronic kidney disease or CKD met its primary efficacy endpoint of a statistically significant improvement in kidney function. La Jolla Pharmaceutical Company (NASDAQ:LJPC)’s stock on Mar 10, 2014 reported an increase of 11.68% to the closing price of $10.90. Its fifty two weeks range is $2.75 -$12.00. The total market capitalization recorded $48.01 million. The overall volume in the last trading session was 1,745,453 million shares. In its share capital, La Jolla Pharmaceutical Company (NASDAQ:LJPC) has 0.55 million outstanding shares.

Aastrom Biosciences, Inc. (NASDAQ:ASTM) entered into a purchase agreement (the “Purchase Agreement”), together with a registration rights agreement (the “Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company has the right to sell to Lincoln Park up to $15,000,000 in shares of its common stock, no par value (“Common Stock”), subject to certain limitations. On Monday, shares of Aastrom Biosciences Inc (NASDAQ:ASTM) advanced 16.07% to close the day at $3.90. Company’s monthly performance is recorded as 14.04%. Aastrom Biosciences Inc (NASDAQ:ASTM) quarterly revenue growth is 6.85%.